Jay Olson
Stock Analyst at Oppenheimer
(3.59)
# 823
Out of 4,944 analysts
243
Total ratings
40.51%
Success rate
8.21%
Average return
Main Sectors:
Stocks Rated by Jay Olson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $44 | $7.88 | +458.38% | 4 | Aug 11, 2025 | |
| MNMD Mind Medicine (MindMed) | Reinstates: Outperform | $25 | $10.24 | +144.14% | 1 | Aug 4, 2025 | |
| ATAI Atai Life Sciences | Initiates: Outperform | $14 | $4.08 | +243.14% | 1 | Jul 29, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $97 → $115 | $49.74 | +131.20% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Perform | $19 → $22 | $25.38 | -13.32% | 15 | Jun 26, 2025 | |
| PRTA Prothena Corporation | Downgrades: Perform | n/a | $7.91 | - | 15 | May 27, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Outperform | $65 | $24.55 | +164.77% | 1 | May 21, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $80 → $65 | $2.93 | +2,118.43% | 5 | May 15, 2025 | |
| INO Inovio Pharmaceuticals | Maintains: Outperform | $15 → $13 | $1.60 | +712.50% | 3 | May 14, 2025 | |
| RVMD Revolution Medicines | Maintains: Outperform | $70 → $75 | $35.29 | +112.52% | 9 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $21 | $3.23 | +550.15% | 2 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $90 | $24.40 | +268.85% | 6 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $42 | $14.03 | +199.36% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $41 → $33 | $38.24 | -13.70% | 6 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $40 | $11.43 | +250.11% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $20 | $1.71 | +1,069.59% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $9.70 | +209.28% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $20 | $6.80 | +194.12% | 2 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $255 | $133.36 | +91.21% | 25 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $82 | $83.49 | -1.78% | 14 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $375 → $350 | $367.38 | -4.73% | 10 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $10 | $3.31 | +202.11% | 4 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $138 | $40.10 | +244.14% | 8 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $1.58 | +406.33% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $380 | $285.93 | +32.90% | 23 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $216 → $219 | $130.55 | +67.75% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $12 | $3.07 | +290.88% | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $3.61 | +398.61% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.79 | +1,166.30% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $95 | $58.50 | +62.39% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $3.08 | +711.69% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $72 → $75 | $42.03 | +78.44% | 3 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $1.26 | +614.29% | 4 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | n/a | $9.44 | - | 6 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,200 → $500 | $1.81 | +27,600.83% | 4 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $25 → $21 | $7.16 | +193.50% | 9 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.58 | - | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $84 | $18.75 | +348.00% | 1 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.10 | - | 3 | Jul 11, 2017 |
Bicycle Therapeutics
Aug 11, 2025
Maintains: Outperform
Price Target: $48 → $44
Current: $7.88
Upside: +458.38%
Mind Medicine (MindMed)
Aug 4, 2025
Reinstates: Outperform
Price Target: $25
Current: $10.24
Upside: +144.14%
Atai Life Sciences
Jul 29, 2025
Initiates: Outperform
Price Target: $14
Current: $4.08
Upside: +243.14%
Praxis Precision Medicines
Jul 8, 2025
Maintains: Outperform
Price Target: $97 → $115
Current: $49.74
Upside: +131.20%
ACADIA Pharmaceuticals
Jun 26, 2025
Maintains: Perform
Price Target: $19 → $22
Current: $25.38
Upside: -13.32%
Prothena Corporation
May 27, 2025
Downgrades: Perform
Price Target: n/a
Current: $7.91
Upside: -
Tvardi Therapeutics
May 21, 2025
Initiates: Outperform
Price Target: $65
Current: $24.55
Upside: +164.77%
Jasper Therapeutics
May 15, 2025
Maintains: Outperform
Price Target: $80 → $65
Current: $2.93
Upside: +2,118.43%
Inovio Pharmaceuticals
May 14, 2025
Maintains: Outperform
Price Target: $15 → $13
Current: $1.60
Upside: +712.50%
Revolution Medicines
May 8, 2025
Maintains: Outperform
Price Target: $70 → $75
Current: $35.29
Upside: +112.52%
May 7, 2025
Maintains: Outperform
Price Target: $25 → $21
Current: $3.23
Upside: +550.15%
Mar 14, 2025
Upgrades: Outperform
Price Target: $90
Current: $24.40
Upside: +268.85%
Mar 3, 2025
Maintains: Outperform
Price Target: $50 → $42
Current: $14.03
Upside: +199.36%
Jan 24, 2025
Downgrades: Perform
Price Target: $41 → $33
Current: $38.24
Upside: -13.70%
Jan 13, 2025
Maintains: Outperform
Price Target: $60 → $40
Current: $11.43
Upside: +250.11%
Dec 11, 2024
Maintains: Outperform
Price Target: $80 → $20
Current: $1.71
Upside: +1,069.59%
Dec 6, 2024
Initiates: Outperform
Price Target: $30
Current: $9.70
Upside: +209.28%
Dec 4, 2024
Maintains: Outperform
Price Target: $17 → $20
Current: $6.80
Upside: +194.12%
Oct 31, 2024
Maintains: Outperform
Price Target: $270 → $255
Current: $133.36
Upside: +91.21%
Oct 30, 2024
Maintains: Outperform
Price Target: $81 → $82
Current: $83.49
Upside: -1.78%
Oct 23, 2024
Maintains: Outperform
Price Target: $375 → $350
Current: $367.38
Upside: -4.73%
Oct 17, 2024
Maintains: Outperform
Price Target: $9 → $10
Current: $3.31
Upside: +202.11%
Sep 25, 2024
Reiterates: Outperform
Price Target: $138
Current: $40.10
Upside: +244.14%
Aug 14, 2024
Assumes: Outperform
Price Target: $8
Current: $1.58
Upside: +406.33%
Aug 7, 2024
Maintains: Outperform
Price Target: $380
Current: $285.93
Upside: +32.90%
Aug 2, 2024
Maintains: Outperform
Price Target: $216 → $219
Current: $130.55
Upside: +67.75%
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $3.07
Upside: +290.88%
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $3.61
Upside: +398.61%
May 15, 2024
Maintains: Outperform
Price Target: $10
Current: $0.79
Upside: +1,166.30%
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $58.50
Upside: +62.39%
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $3.08
Upside: +711.69%
Apr 9, 2024
Maintains: Outperform
Price Target: $72 → $75
Current: $42.03
Upside: +78.44%
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $1.26
Upside: +614.29%
Mar 5, 2024
Maintains: Perform
Price Target: n/a
Current: $9.44
Upside: -
Nov 30, 2023
Maintains: Outperform
Price Target: $1,200 → $500
Current: $1.81
Upside: +27,600.83%
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $7.16
Upside: +193.50%
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $0.58
Upside: -
Mar 20, 2018
Maintains: Outperform
Price Target: $70 → $84
Current: $18.75
Upside: +348.00%
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.10
Upside: -